These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25026312)

  • 1. Sweet escape: sialic acids in tumor immune evasion.
    Büll C; den Brok MH; Adema GJ
    Biochim Biophys Acta; 2014 Aug; 1846(1):238-46. PubMed ID: 25026312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Siglec Signaling in the Tumor Microenvironment.
    van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
    Front Immunol; 2021; 12():790317. PubMed ID: 34966391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
    van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
    Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
    Bärenwaldt A; Läubli H
    Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.
    Adams OJ; Stanczak MA; von Gunten S; Läubli H
    Glycobiology; 2018 Sep; 28(9):640-647. PubMed ID: 29309569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innate immune mediators in cancer: between defense and resistance.
    Berraondo P; Minute L; Ajona D; Corrales L; Melero I; Pio R
    Immunol Rev; 2016 Nov; 274(1):290-306. PubMed ID: 27782320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells.
    Poggi A; Musso A; Dapino I; Zocchi MR
    Immunol Lett; 2014; 159(1-2):55-72. PubMed ID: 24657523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
    Boelaars K; van Kooyk Y
    Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-glucan restores tumor-educated dendritic cell maturation to enhance antitumor immune responses.
    Ning Y; Xu D; Zhang X; Bai Y; Ding J; Feng T; Wang S; Xu N; Qian K; Wang Y; Qi C
    Int J Cancer; 2016 Jun; 138(11):2713-23. PubMed ID: 26773960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies of tumor immune evasion.
    Seliger B
    BioDrugs; 2005; 19(6):347-54. PubMed ID: 16392887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sialic acids in cancer biology and immunity.
    Pearce OM; Läubli H
    Glycobiology; 2016 Feb; 26(2):111-28. PubMed ID: 26518624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-host immune interactions and dendritic cell dysfunction.
    Yang L; Carbone DP
    Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCL21 Programs Immune Activity in Tumor Microenvironment.
    Sharma S; Kadam P; Dubinett S
    Adv Exp Med Biol; 2020; 1231():67-78. PubMed ID: 32060847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sialylation acts as a checkpoint for innate immune responses in the central nervous system.
    Klaus C; Liao H; Allendorf DH; Brown GC; Neumann H
    Glia; 2021 Jul; 69(7):1619-1636. PubMed ID: 33340149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of sialic acid metabolism drives tumor growth by augmenting CD8
    Cornelissen LAM; Blanas A; van der Horst JC; Kruijssen L; Zaal A; O'Toole T; Wiercx L; van Kooyk Y; van Vliet SJ
    Int J Cancer; 2019 May; 144(9):2290-2302. PubMed ID: 30578646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.
    Rolinski J; Hus I
    J Immunotoxicol; 2014 Oct; 11(4):311-8. PubMed ID: 24495309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immune system and cancer evasion strategies: therapeutic concepts.
    Muenst S; Läubli H; Soysal SD; Zippelius A; Tzankov A; Hoeller S
    J Intern Med; 2016 Jun; 279(6):541-62. PubMed ID: 26748421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innate immune recognition of cancer.
    Woo SR; Corrales L; Gajewski TF
    Annu Rev Immunol; 2015; 33():445-74. PubMed ID: 25622193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen specificity of immune suppression by myeloid-derived suppressor cells.
    Solito S; Bronte V; Mandruzzato S
    J Leukoc Biol; 2011 Jul; 90(1):31-6. PubMed ID: 21486906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy.
    Feng H; Feng J; Han X; Ying Y; Lou W; Liu L; Zhang L
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.